Yes, Clopidogrel can reduce the risk of recurrent ischemic events by inhibiting platelet aggregation, thereby preventing thrombosis in arterial circulation.

Clopidogrel is used in secondary prevention of thrombotic complications by blocking the ADP receptor on platelets, reducing clot formation.

Yes, Clopidogrel lowers the risk of strokes and heart attacks in patients with past ischemic events by preventing platelet clumping.

Clopidogrel helps in secondary prevention of thrombotic events by irreversibly binding to platelet receptors, thus inhibiting clot formation.

By preventing platelet aggregation, Clopidogrel reduces the likelihood of recurrent ischemic events and is essential for secondary thrombotic risk management.